NeuroAIDS

The introduction of combination antiretroviral treatment (cART) has led to a large decrease in the incidence of HIV-Associated Dementia (HAD). However, cART has not been shown to decrease the incidence of all neurocognitive impairment, and minor forms of neurocognitive impairment still persist at similar rates pre- and post-cART. These types of neurocognitive impairments can have a significant impact on daily functioning and, as a result, there is an emerging demand for screening tools that not only detect impairment but that are also brief and cost-effective for use in clinical settings. To inform the research agenda in the field of screening tools for HAD and especially minor neurocognitive impairment associated with HIV, we are currently systematically reviewing and synthesizing the literature in this area. From this synthesis, we hope to be able to identify one or more valid, brief and cost-effective screening tools for neurocognitive impairments for HAD.

To date we have completed extensive literature searches, reviewed the results and identified a set of relevant papers, which we will use to conduct our synthesis.

Sign up for our monthly newsletter

Get our “Did you know” — our monthly newsletter, and updates and announcements from the OHTN.


Opt into another list

×
WordPress Image Lightbox Plugin